Loading...
XJPX4564
Market cap39mUSD
Jan 21, Last price  
23.00JPY
1D
0.00%
1Q
-25.81%
Jan 2017
-91.45%
Name

OncoTherapy Science Inc

Chart & Performance

D1W1MN
XJPX:4564 chart
P/E
P/S
10.24
EPS
Div Yield, %
Shrs. gr., 5y
7.60%
Rev. gr., 5y
16.81%
Revenues
610m
-46.24%
1,580,000,0001,164,764,000804,491,0001,972,835,0003,327,575,0005,257,628,0005,361,397,0006,223,947,0003,277,411,0001,017,769,000769,956,000266,903,000286,667,000211,251,000280,586,000316,215,000332,477,0001,153,663,0001,134,903,000610,118,000
Net income
-1.29b
L+15.15%
17,392,000-525,700,000-1,323,362,000-202,073,000148,249,000510,159,000566,758,000726,961,000-1,103,203,000-3,676,647,000-1,334,890,000-2,788,819,000-3,002,063,000-2,851,092,000-2,934,960,000-2,238,558,000-1,561,636,000-2,571,541,000-1,118,644,000-1,288,138,000
CFO
-1.23b
L+54.48%
279,073,000-550,898,000-1,091,497,000346,225,000-223,504,0001,024,616,000440,961,000-91,325,000-455,654,000-1,649,667,000-1,702,607,000-2,898,286,000-2,988,040,000-3,035,947,000-2,373,427,000-2,275,529,000-1,762,629,000-2,073,224,000-794,901,000-1,227,990,000
Earnings
Feb 07, 2025

Profile

OncoTherapy Science, Inc. researches and develops anti-cancer medicines and therapies in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a T-LAK cell-originated protein kinase inhibitor for the treatment of various cancer diseases. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. Further, the company provides contract analysis services. OncoTherapy Science, Inc. was founded in 2001 and is headquartered in Kawasaki, Japan.
IPO date
Dec 08, 2003
Employees
60
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
610,118
-46.24%
1,134,903
-1.63%
1,153,663
246.99%
Cost of revenue
1,730,917
2,241,318
3,206,300
Unusual Expense (Income)
NOPBT
(1,120,799)
(1,106,415)
(2,052,637)
NOPBT Margin
Operating Taxes
2,425
2,223
1,234
Tax Rate
NOPAT
(1,123,224)
(1,108,638)
(2,053,871)
Net income
(1,288,138)
15.15%
(1,118,644)
-56.50%
(2,571,541)
64.67%
Dividends
Dividend yield
Proceeds from repurchase of equity
682,552
1,466,717
BB yield
-16.04%
-11.34%
Debt
Debt current
Long-term debt
106,849
Deferred revenue
Other long-term liabilities
47,165
47,046
99,706
Net debt
(469,807)
(1,206,635)
(1,920,906)
Cash flow
Cash from operating activities
(1,227,990)
(794,901)
(2,073,224)
CAPEX
(2,627)
(5,393)
(456,949)
Cash from investing activities
(33,354)
(20,319)
(467,928)
Cash from financing activities
671,365
95,950
1,478,967
FCF
(1,123,224)
(949,899)
(2,017,582)
Balance
Cash
527,656
1,117,635
1,836,906
Long term investments
49,000
89,000
84,000
Excess cash
546,150
1,149,890
1,863,223
Stockholders' equity
(25,969,962)
(23,938,449)
(22,813,385)
Invested Capital
26,477,644
24,771,283
24,756,790
ROIC
ROCE
EV
Common stock shares outstanding
212,783
192,644
187,466
Price
20.00
-57.45%
47.00
-31.88%
69.00
-43.90%
Market cap
4,255,669
-53.00%
9,054,254
-30.00%
12,935,172
-40.36%
EV
3,785,862
7,847,619
11,014,266
EBITDA
(1,120,799)
(1,106,415)
(2,036,097)
EV/EBITDA
Interest
218
5,372
Interest/NOPBT